Summary: The CYP3A4 enzyme is known for its atypical inhibition kinetics; ligand inhibition can diŠer depending upon the probe drug used. A high throughput-LCMS W MS CYP3A4 inhibition assay with four substrate drugs was developed to minimize the potential oversight of CYP3A4 inhibition. The assay uses a 96-well format, human liver microsomes, and four CYP3A4 substrate drugs, midazolam, testosterone, nifedipine and terfenadine. After incubation of the individual substrate with human liver microsomes, the reaction is stopped by solid phase extraction and the four probe metabolites produced are pooled and measured by LCMS W MS with multiple-ion-monitoring mode. Using this assay, the IC 50 values of fourteen compounds recognized as substrates W inhibitors of CYP3A4, were measured for the CYP3A4 catalyzed-metabolism of probe drugs. IC 50 values were also obtained for the common set of compounds by the microtiter plate ‰uorescent assays with cDNA-expressed CYP3A4. Comparison of the results from the two methods suggests that decision making should be cautiously executed to predict drug interaction potential caused by inhibition of CYP3A4 considering the gap between the two assays and various other factors.
Introduction
Advent of combinatory chemistry and high throughput screening technologies has resulted in a paradigm shift in drug discovery and development during the last decade. Numerous strategies have been developed to predict potential clinical risks in drug metabolism and pharmacokinetics (DMPK), as it has been recognized that failure in the clinical use of a drug results from inadequate DMPK properties of drugs in many cases. Signiˆcant eŠorts are continuously under way today toward a consensus of an optimized drug development strategy. [1] [2] [3] Pharmacokinetic drug-drug interaction (DDI) potential is a major concern in the pharmaceutical industry.
4) The majority of clinical drugs are metabolized by liver cytochrome P450 (CYP) enzymes.
A number of in vitro methods have been developed to assess the potential risk of CYP inhibition DDI. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] CYP3A4 is expressed as the most abundant constituent in the human liver CYP enzyme system 15) and is also expressed at substantial levels in the intestinal epithelial cells to metabolize orally administered drugs. 16) CYP3A4 is the most important drug metabolizing enzyme that metabolizes, by remarkably diverse catalytic processes, more than 50z of clinical drugs and a wide variety of other xenobiotics as well as endogenous substrates. 17) Although beneˆcial combination therapy utilizing CYP3A4 inhibition has been reported, clinical DDI due to CYP3A4 inhibition often resulted in serious clinical consequences. 1, 18) The characteristic nature of CYP3A4 as an enzyme has been shown by the atypical enzyme kinetic behavior. The large substrate binding site can accommodate multiple substrates or multiple conformers simultaneously. 19) The ligand binding sites of CYP3A4 can show marked catalytic regiospeciˆcity and they have a diŠer-ent role in altering substrate speciˆcity, protein structure and cooperativity. [20] [21] [22] EŠects of ligands on CYP3A4 activity are diŠerent depending upon the structure of probe substrates. 23, 24) In order to accurately assess the CYP3A4 DDI potential, diŠerent classes of CYP3A4 probe substrates must be used to minimize the possible oversight derived from use of only one class of CYP3A4 probe substrates.
In the current paper, we report the development of a high throughput (HT)-LCMS W MS method with four structurally diŠerent probe substrates to assess the potential for CYP3A4 inhibition by drug candidates. The current method is a sister version of our previously developed seven CYP inhibition assay (multiple-ion monitoring LCMS W MS) using CYP isoform speciˆc probe substrates and a human liver microsome pool. 13) The present probe substrates used are midazolam, testosterone, nifedipine and terfenadine, and the enzyme source is a human liver microsome pool.
The IC50 values of fourteen compounds known as CYP3A4 inhibitors or substrates were determined by the validated method and their inhibition proˆles were compared for each of the four diŠerent probe substrates. In addition, IC 50 values for the same set of fourteen compounds were obtained by the microtiter plate ‰uorescent assay with cDNA-expressed CYP3A4 26) and compared with the HT-LCMS W MS data.
This comparison was conducted to understand the gap between two CYP3A4 inhibition assays. The microtiter plate HT assay is widely used for early screening or lead optimization and the HT-LCMS W MS assay is used for preclinical development support. Furthermore, points to be considered for decision making in drug development are reviewed. Microsomal incubations: Incubation mixtures contained aˆnal concentration of 0.04 mg W mL microsomal protein in 0.1 M potassium phosphate buŠer (pH 7.4), 5 mM MgCl 2 , 1 mM EDTA and 1 mM NADPH in a total volume of 0.5 mL. The probe substrates and their nal concentrations for the human CYP3A4, were 5 mM midazolam, 70 mM testosterone, 2.5 mM terfenadine and 10 mM nifedipine. A 500-fold concentration of each substrate stock solution was prepared in methanol; 1 mL was added into 0.5 mL of incubation mixture (technically this was achieved by preparing a pool for 15 incubation to make 15 aliquots, so that each aliquot might contain 1 mL of methanol). Concentrations used were Fig. 1 . After the 10 minute incubation at 379 C (shaking at 80 strokes per minute), an aliquot of reaction mixture (0.45 mL) was transferred onto a preconditioned SPE plate to immediately stop the reactions by removing the NADPH cofactor from the incubation mixture. All extraction procedures were carried out on a Tomtec Quadra 96 TM multi-well plate processor as described later.
The inhibition of the catalytic activity of each CYP3A4 probe substrate was evaluated for fourteen test compounds; twelve concentrations of each test compound were used. For each test compound (inhibitor), a 100-fold dilution range was prepared in 80z methanol; 5 mL was added into 0.5 mL of incubation mixture. Thê nal concentrations used for each inhibitor were: 0 mM (control), 0.001 mM, 0.005 mM, 0.01 mM, 0.05 mM, 0.10 mM, 0.50 mM, 1.0 mM, 5.0 mM, 10 mM, 50 mM and 100 mM. Theˆnal methanol concentration in the incubations was 1z (V W V).
For the determination of inter-assay variability, experiments were carried out in duplicate and repeated for three consecutive days. For the determination of intraassay variability, experiments were carried out in duplicate in four sets on the same day. For the determination of the linear time course range of each reaction, a series of incubations were carried out under the same conditions and the reactions were stopped at 0, 5, 10 and 20 min. For protein linearity determinations, the incubations were carried out using a human liver microsomal protein concentration of 0 to 1.0 mg W mL (0, 0.05, 0.10, 0.20, 0.30, 0.50, and 1.0 mg W mL) and the reactions were terminated at 10 min.
Solid phase extraction (SPE): The reactions were terminated and the metabolites were extracted using OASIS HLB 96-well SPE plates that contain 30 mg macroporous copolymer, [poly(divinylbenzene-co-Nvinylpyrrolidone)] per well from Waters Corporation (Milford, MA). A Tomtec Quadra 96 TM liquid handling system (Tomtec, Inc., Hamden, CT) was used for the sample transfers and extractions. The SPE plates were pre-conditioned with 0.8 mL of methanol followed by 0.8 mL of distilled water. Microsomal incubations (0.45 mL) were transferred onto the plates and the reactions were terminated with 1.0 mL of distilled water. The metabolites were eluted with 0.7 mL of methanol into 96-well collection plates. A vacuum from 2 to 10 mm Hg was applied during sample transfer and extraction. Following extraction, aliquots (50 mL) of eluent from each row (from each of the four diŠerent probe substrates i.e. rows ABCD and rows EFGH, as shown in Fig. 1 ) were pooled to generate two sets of 12 samples each. An aliquot (50 mL) of internal standard (0.30 mM stock of 4?-hydroxyphenytoin) was added into each well and the samples were evaporated to dryness under nitrogen gas in a Turbo Vap 96 (Zymark Corp., Hopkinton, MA) set at 379 C. The evaporated extracts were reconstituted in 200 mL of 50 W 50 (v W v) methanol W water containing 0.1z acetic acid andˆltered using micro-centrifuge tubes (0.22 mm nylon, Analytical Sales and Service, Mahwah, NJ). The samples were then analyzed by LCMS W MS in multiple reaction monitoring mode (MRM) .
LCMS W MS analysis: The quantiˆcation of metabolites was performed using a Hewlet Packard 1100 HPLC instrument,ˆtted with a Leap autosampler (LEAP Technologies, Carrboro, NC), coupled to a Micromass (Manchester, UK) Quattro II triple quadrapole mass detector with an electrospray ionization source. A Phenomenex column: Aqua 5 mm C18 125 Å, 2 ×50 mm (Phenomenex, Torrance, CA) was used for separation. The column temperature was set at 309 C. The mobile phase consisted of 0.1z acetic acid in water (A) and 0.1z (V W V) acetic acid in methanol (B). The initial condition was set at 45z (V W V) B, remained at initial condition for 0.5 minutes, then increased to 80z B over 5.5 minutes, remained at 80z B for 3.5 minutes, then brought back to initial condition in 0.5 minute. The total run time was 14 minutes at a ‰ow rate of 0.2 mL W minute. A 25 mL aliquot was injected onto the column and the initial 1.5 minutes of eluent was diverted to waste. The operating parameters of the MS detector were set as follows: capillary voltage 2.0 KV, resolution 15 for both low mass (LM) and high mass (HM), drying gas ‰ow rate¿350 L W hr, and source temperature 1209 C. The scan function parameters, including cone voltages and collision energies were optimized to accommodate all analytes and are listed in Table 1 . The structures of probe substrates and metabolites used in this assay are shown in Fig. 2 . A typical LCMS W MS chromatogram showing MRM transitions of all four probe metabolites and internal standard (4?-hydroxyphenytoin) is shown in Fig. 3 . 
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Linearity and assay variation:
The linearity of the calibration curve for the metabolite of each probe substrate was established from 0 to 5000 ng W mL. Each metabolite was spiked into an incubation mixture without the corresponding substrates and NADPH, and was then extracted and analyzed by LCMS W MS as described above. Intra-day assay variation (CVz) for the control and positive inhibitor (ketoconazole) samples was calculated from the results of duplicate samples in four diŠerent incubation sets within one day. Inter-day assay variation (CVz) for the control and positive inhibitor (ketoconazole) samples was calculated from the results of duplicate incubation sets on three diŠerent days. The assay variations of the control samples were calculated using analyte W IS ratio. The assay variations for the positive controls were calculated using percent of control activity remaining. The percent control activity remaining was calculated with the following equation: (IS ratio with inhibitor W IS ratio of control)×100z. The percent inhibition can be calculated by subtracting the percent activity remaining from 100.
Determination of Km values: A series of preliminary experiments were conducted to establish the K m values for each substrate probe; theˆnal concentration range was three orders of magnitude (0, 0.01, 0.05, 0.10, 0.50, 1.0, 1.5, 2, 5 and 10×literature Km value) for each substrate probe ( The mean±SD and the percent coe‹ci-ent of variation (CVz) were used to describe variability.
Microtiter plate assay using ‰uorometric substrates: Assay procedures, reagents and format are found in WWW.GENTEST.COM. In order to compare IC50 values obtained from two diŠerent laboratories, test ligands for CYP3A4 inhibition and ‰uorometric substrates in the current CYP3A4 inhibition assay were selected from the previous report. 26) Three ‰uorometric substrates, 7-benzyloxyquinoline (BQ), 7-benzyloxy-4-tri‰uoromethylcoumarin (BFC) and dibenzyl ‰uores-cein (DBF) were used for the current microtiter plate CYP3A4 inhibition assay.
Results
Analytical characteristics and linearity: CYP3A4 metabolites and the internal standard were eluted from approximately 2 to 5.5 min, and their LCMS W MS chromatograms and scan function parameters are shown in Fig. 3 and Table 1 , respectively. Enzyme activity was expressed as formation of four characteristic metabolites, measured as peak area ratio of metabolite over IS. A linear relationship of probe metabolite concentration to peak area was detected by LCMS W MS in MRM mode in a range of 3-7300 nM for 1?-hydroxy midazolam, 5-5125 nM for t-butylhydroxy terfenadine, 3-7250 nM for oxidized nifedipine and 33-8510 nM for 6b-hydroxy testosterone.
The linear relationship between metabolite production and microsome concentration was demonstrated for each probe. At substrate concentrations of approximately K m values, and a protein concentration of 0.2 mg W mL, the reactions for all four marker probes were linear up to 10 minutes. The subsequent experiments used a reaction time of 10 minutes and 0.04 mg W mL protein. Under these conditions, consumptions of all four probe substrates after 10 minutes of incubation in the absence of test compounds were all well below 20z of the added substrates.
Assay variation: Three incubations per inhibitor concentration were performed for inter-day variation experiments and four incubations per inhibitor concentration were performed for intra-day variation experiments. Each sample in both of these experiments was analyzed twice by LCMS W MS. CVz values of all four metabolites in the intra-day and inter-day variation of control samples were 3.24 and 3.22z for 1?-hydroxy midazolam, 0.35 and 0.32z for 6b-hydroxy testosterone, 9.96 and 8.79z for oxidized nifedipine and 0.82 and 0.76z for t-butylhydroxy terfenadine, respectively. Intra-day and inter-day assay variation of the CYP3A4 inhibitor, ketoconazole for each reaction were evaluated. CVz values of all four metabolites in the intra-day and inter-day variation of ketoconazole were 2.47-14.94z and 1.12-7.04z for 1?-hydroxy midazolam, 2.01-11.01z and 1.05-25.47z for 6b-hydroxy testosterone, 0.58-13.08z and 1.17-10.63z for oxidized nifedipine and 2.23-8.17z and 0.93-4.65z for tbutylhydroxy terfenadine, respectively. The estimated IC50 values of ketoconazole for the four CYP3A4 mediated oxidation from inter-day validation data are 0.026 mM for 1?-hydroxylation of midazolam, 0.054 mM for 6b-hydroxylation of testosterone, 0.023 mM for oxidized nifedipine and 0.2 mM for t-butylhydroxylation of terfenadine and are shown in Table 3 .
Km determination: As part of the method develop- Substrate Activation À50 Activation Activation Activation＋Inhibition* À1000 Activation 32.11 Activation Activation Activation＋Inhibition* HT-LCMS W MS: Probe substrate used; midazolam (5 mM), testosterone (70 mM), nifedipine (10 mM) and terfenadine (2.5 mM). Microtiter plate ‰uorescent assay: two IC 50 values were obtained from two independent runs of single tube W concnetration assay, using dimethyl sulfoxide (DMSO) or acetonitrile (ACN) solvent. Fluorogenic substrate used: BQ, 7-benzyloxyquinoline; BFC, 7-benzyloxy-4-tri‰uoromethyl-coumarin; DBF, dibenzyl ‰uorescein. * Initial activation followed by inhibition. ment, the Km value of each probe reaction was measured ( Table 2) . Km values for metabolite formation for each probe were obtained from the Michaelis-Menten enzyme kinetics equation. The experimentally derived Km value for midazolam (3.27±0.50 mM), testosterone (67.4±5.48 mM) and nifedipine (9.31±3.24 mM) approximated the respective literature values as shown in Table 2 . The experimentally derived value for terfenadine (2.1±0.3 mM) was a little lower than the literature values.
Inhibition study with known CYP3A4 inhibitors and substrates: Ketoconazole was used as the reference inhibitor in the assay.
IC50 values of fourteen CYP3A4 inhibitors W substrates were determined at various concentration levels (0.001-100 mM) using the HT-LCMS W MS assay. This inhibition assay was performed by``Real high throughput mode'' (single incubation per concentration and duplicate injections to LCMS per each sample). Graphically obtained IC50 values of CYP3A4 inhibitors from theˆgures are presented in Table 4 . IC50 values of ketoconazole were 0.006 mM, 0.015 mM, 0.005 mM and 0.07 mM for 1?-hydroxylation of midazolam, 6b-hydroxylation of testosterone, nifedipine oxidation and for t-butylhydroxylation of terfenadine, respectively. These IC50 values did not lie within the assay variation observed. This discrepancy might originate from the enzyme source used; the lots of the human liver microsome pool used in the inhibition assay and variation assay were not the same.
Microtiter plate ‰uorescent assay: IC50 values obtained from microtiter plate ‰uorescent assays by two diŠerent laboratories are presented in Table 4 . A discovery group in Roche used dimethyl sulfoxide (DMSO) as solvent and the assay was performed by``Real high throughput mode'' (single tube incubation per concentration) twice independently. The eŠect of solvent was investigated for four test compounds (cisapride, midazolam, nifedipine and verapamil) using acetonitrile (ACN). Results from Stresser et al. 26) are presented for comparison in the same table.
Discussion
Kenworthy et al. categorized probe substrates for CYP3A4 inhibition kinetics, where testosterone belongs to one group together with erythromycin and cyclosporin while midazolam is in the second group together with dextromethorphan, diazepam and triazolam. These two groups are distinct from each other in their kinetic behavior. Terfenadine can well belong to either group, while nifedipine shows a unique property from terfenadine and the two groups. 30) Therefore, the set of probe substrates used in the HT-LCMS W MS CYP3A4 inhibition assay is composed of four substrates that represent the four probe categories.
As shown in Table 4 , generally, very strong CYP3A4 inhibitors such as itraconazole, ketoconazole, miconazole and clotrimazole showed IC50 values below 1 mM regardless of the probe substrate used. One exception is inhibition of terfenadine metabolism by itraconazole. Itraconazole's IC50 to terfenadine metabolism obtained in this study is somehow contradictory to the proposed categorization by Kenworthy et al. 30) In the presence of itraconazole, CYP3A4 appears to have metabolized terfenadine in a diŠerent manner from the other probe drugs.
CYP3A4 substrate drugs have been implicated in serious clinical drug interactions. Mibefradil, 31) cyclosporin, 31, 32) cisapride 34) and terfenadine 33) exhibited largely diŠerent IC50 values depending upon the probe substrates used; which ranged from 0.2 to 2 mM, 1.5 to over 50 mM, 1 to 10 mM and 4 to 50 mM, respectively. These facts clearly indicate that in vitro DDI assessment with CYP3A4 must be performed using multi-probe substrate drugs. Ideally DDI assessment must be conducted using clinically feasible concomitant drugs from both directions, as a substrate to be aŠected or as a potential inhibitor or activator.
As shown in Table 4 , notable activation of CYP3A4 by testosterone and a-naphtho‰avone was observed in both HT-LCMS W MS and ‰uorescent assays. This is a previously known characteristic phenomenon of CYP3A4. 24, 26, 27) Such activation of DDI may potentially occur in the clinic.
In the current studies, comparison of IC50 values from the LCMS W MS assay and microtiter plate ‰uorescence assay was evaluated. The ‰uorescence assay is routinely used for discovery support and compound screening to reduce the large number of chemical entities toward the lead selection, generally after in silico evaluation if it is implemented, 34) while the LCMS W MS assay is used for late development support before entry into human studies (EIH).
A bridging was necessary at some point to understand in house data produced by diŠerent functional groups. Microtiter plate ‰uorescence assay was performed using three ‰uorometric substrates according to the manufacturer's procedure, 26) except for the solvent. Our assay used dimethyl sulfoxide (DMSO) while the manufacturer used acetonitrile (ACN) as indicated in Table 4 . Solvent eŠects on CYP activities have been previously reported by diŠerent groups. [36] [37] [38] However, in house IC50 values of the fourteen ligands generally fall within several fold diŠerences from the data by Stresser et al., 26) except for the cases of mibefradil and cyclosporin, of which more than 20 fold and 100 fold diŠerences are seen with BFC and BQ probes for unknown reasons.
It was investigated if there was any similarity between ‰uorescent probes and drug probes in terms of the categorization by Kenworthy, 30) however, a general rule could not be extracted from the available comparison data. Stresser et al. made a similar comparison and no characteristic diŠerences were found among ‰uorescent probes. 26) It is not surprising to see diŠerent IC 50 values between diŠerent assays that use diŠerent enzyme sources and probe substrates. The HT-LCMS W MS assay uses a human liver microsome pool of 29 individuals and real drugs, while the microtiter plate ‰uorescence assay uses insect cell microsomes expressing cDNA-CYP3A4 and ‰uorogenic chemicals. Fluorescent probes are not CYP isoform speciˆc, therefore only cDNA expressed CYP3A4 isoform is required for speciˆc inhibition assay. It should be recognized that there is always the potential risk of ‰uorescence modiˆcation by chemical interaction with test compounds or solvent used; such artifacts are not due to CYP inhibition. Control incubations should be included in the ‰uorescent assay to monitor such changes.
Bridging between cDNA-expressed CYP and human liver microsomes has been conducted in an attempt to evaluate the gap between the two systems. 40) cDNAexpressed CYP3A4 activities are aŠected by levels of coexpressed reductase and cytochrome b5 and their expression levels are variable across preparations. 41) Taking such factors into consideration, eŠorts have been made to scale up in vitro CYP3A4 inhibition data to predict in vivo DDI. 39, 42) The pharmaceutical industry is now facing challenges toward individual patient prescription for optimized drug therapy because of genetic polymorphism. 44) Very high interindividual variability, possibly several hundred fold diŠerences, exists in the CYP3A enzyme activities. 43 ) Genetic polymorphism does not explain the high variability at present, since the large diŠerences in the activity are well correlated with the expression levels of CYP protein. 43, 45) Possible causes for the very high interindvidual variability have been investigated from various aspects. 46) Other diverse factors including individual variability in inhibition and induction of CYPs will eventually have to be taken into consideration for successful drug therapy and clinical risk prediction. 42) In conclusion, the high throughput microtiter plate ‰uorescent assay is useful to screen numerous chemicals toward lead selection. For this purpose, our data support the manufacturer'sˆnding that BFC seems to be generally the most sensitive probe compound to pick up chemical entities that have CYP3A4 inhibition potential.
On the other hand, to predict potential DDI in the late preclinical development stage, it is absolutely necessary to use probe drugs for which in vitro enzyme kinetics are well characterized and clinical information on the pharmacokinetics and the DDI is abundant.
